Talk:Phosphodiesterase inhibitor

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Phosphodiesterase inhibitor.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

PDE inhibitors

Is it true that PDE inhibitors "block the inhibition of cAMP"? I thought PDE has to do with the inositol business instead. AxelBoldt 09:16 Sep 3, 2002 (PDT)

I think that AxelBoldt, 16 years ago, was thinking about Phospholipase C and its frieds.

Resolved

Klbrain (talk) 20:22, 30 March 2018 (UTC)[reply]

Luteolin

Luteolin is a PDE-4 inhibitor: Eur J Pharmacol. 2009 Oct 22. [Epub ahead of print] Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [(3)H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. Yu MC, Chen JH, Lai CY, Han CY, Ko WC.

Department of Internal Medicine, Taipei Municipal Wan-Fang Hospital, Taiwan. The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [(3)H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic alpha(2)-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an alpha(2)-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30muM) competitively inhibited PDE1-5 activities, with K(i) values of 15.0, 6.4, 13.9, 11.1, and 9.5muM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (K(d)) and maximal density (B(max)) for [(3)H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1nM and 3.7pmol/g of tissue, respectively. The EC(50) (PDE4(H)) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2nM [(3)H]-rolipram binding were 11.2muM and 45.6nM, respectively. The therapeutic (PDE4(H)/PDE4(L)) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30mumol/kg, s.c.) and Ro 20-1724 (0.1-1mumol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4(H)/PDE4(L)) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.

PMID: 19853596

Bixbyte (talk) 22:49, 6 November 2009 (UTC)Bixbyte[reply]

That is not under dispute. Klbrain (talk) 20:22, 30 March 2018 (UTC)[reply]

What does it do?

Can someone add at least a brief sentence describing the general effects in human terms? (E.g., does it cause hallucinations or does it cure diarrhea?) Thanks! bogdanb (talk) 17:03, 21 May 2010 (UTC)[reply]

Add a sentence to the lede; pity this has been missing for so long: actions on brain, lungs, penis, and many more.

Resolved

Klbrain (talk) 20:22, 30 March 2018 (UTC)[reply]